Details of the Drug Combinations

General Information of This Drug (ID: DMHM7JS)

Drug Name

Pasireotide DMHM7JS

Synonyms

Signifor; UNII-I4P76SY3N4; Pasireotide diaspartate; I4P76SY3N4; SOM230; 820232-50-6; pasireotide aspartate; Pasireotide diaspartate [EMA EPAR]; CHEBI:72313; Cyclo((2R)-2-phenylglycyl-d-tryptophyl-l-lysyl-o-(phenylmethyl)-l-tyrosyl-l-phenylalanyl-(4R)-4-((((2-aminoethyl)amino)carbonyl)oxy)-l-prolyl), l-aspartate; Signifor (TN); SOM 230; SOM-230

Indication

Disease Entry	ICD 11	Status	REF
Cushing disease	5A70	Approved	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL is unavailable

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

3 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Everolimus + Pasireotide	DCQB2UD	Everolimus	Neuroendocrine Tumors	[2]
Everolimus + Pasireotide	DCYC3YR	Everolimus	Castrate Resistant Prostate Cancer	[3]
Pasireotide + Diazoxide	DCEGWLN	Diazoxide	Gastro-enteropancreatic Neuroendocrine Tumor	[4]
------------------------------------------------------------------------------------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	ClinicalTrials.gov (NCT01469572) Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases
3	ClinicalTrials.gov (NCT01313559) Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
4	ClinicalTrials.gov (NCT02779257) Pasireotide Treatment for Neuroendocrine Tumor